Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06429722 · ClinicalTrials.gov registry record · Phase 2
To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.
A Phase 2 study of Major Depressive Episode Associated With Bipolar II Disorder, sponsored by Neumora Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 20
- Study locations
NCT06429722: Completed Phase 2 study of Major Depressive Episode Associated With Bipolar II Disorder, sponsored by Neumora Therapeutics.
NCT06429722 is a Phase 2 study of Major Depressive Episode Associated With Bipolar II Disorder that has completed, run by Neumora Therapeutics. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06429722, a Phase 2 study of Major Depressive Episode Associated With Bipolar II Disorder, has completed, sponsored by Neumora Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled pilot study aiming to evaluate the effects of NMRA-335140 on symptoms of major depression in adults with Bipolar (BP) II disorder. The study design consists of a Screening Period (up to 28 days), a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo), and a 6-week Safety Follow-up Period.
Primary Outcome
The MADRS is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants are rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item will be scored on a 7- point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity. Thus, scores in the MADRS range from 0
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NMRA-335140 80 mg
Study Locations (20)
Florida
- Neumora Investigator Site - Gainesville
- Neumora Investigator Site - Lauderhill
- Neumora Investigator Site - Maitland
- Neumora Investigator Site - Miami
- Neumora Investigator Site - Miami Lakes
California
- Neumora Investigator Site - Garden Grove
- Neumora Investigator Site - Long Beach
- Neumora Investigator Site - San Jose
- Neumora Investigator Site - Torrance
New Jersey
- Neumora Investigator Site - Marlton
- Neumora Investigator Site - Princeton
- Neumora Investigator Site - Toms River
Georgia
- Neumora Investigator Site - Marietta
- Neumora Investigator Site - Savannah
Arizona
- Neumora Investigator Site - Phoenix
Arkansas
- Neumora Investigator Site - Little Rock
Massachusetts
- Neumora Investigator Site - Watertown
Mississippi
- Neumora Investigator Site - Flowood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-05-13 |
| Est. Completion | 2025-05-30 |
| Phase | Phase 2 |
What the finished NCT06429722 record still lists
NCT06429722 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Major Depressive Episode Associated With Bipolar II Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06429722 names 20 study sites across 10 states, led by Florida, California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06429722 about?
NCT06429722 is a clinical study titled "To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.". This is a randomized, double-blind, placebo-controlled pilot study aiming to evaluate the effects of NMRA-335140 on symptoms of major depression in adults with Bipolar (BP) II disorder. The study design consists of a Screening Period (up to 28 days), a 6-week Treatment Period (during which participa...
What is the current status of trial NCT06429722?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2024-05-13. Estimated completion is 2025-05-30.
What conditions does trial NCT06429722 study?
This clinical trial studies the following conditions: Major Depressive Episode Associated With Bipolar II Disorder.
What interventions are being tested in trial NCT06429722?
The interventions under investigation include: Placebo (DRUG), NMRA-335140 80 mg (DRUG).
Who is sponsoring clinical trial NCT06429722?
This trial is sponsored by Neumora Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06429722 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06429722's enrollment target sits among peer trials
18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI